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Because hypertension causes end-organ damage and cardiovascular disease, proper treatment is extremely
important to prevent progression. Secondary and essential hypertension, respectively, are classified by whether
the specific etiology is known or unknown. Secondary hypertension includes renal parenchymal hypertension,
renovascular hypertension, and endocrine hypertension, among others. In essential hypertension, genetic and en-
vironmental factors and adaptations to neural, mechanical, and hormonal perturbations interact to raise blood
pressure. In many cases of secondary hypertension, blood pressure can be effectively reduced by treating the eti-
ology. Therefore, it is important to identify secondary hypertension. In patients with essential hypertension,
treatment consists of lifestyle modification and appropriate drug therapy, with use of calcium channel blockers,
angiotensin-receptor blockers, angiotensin-converting enzyme inhibitors, diuretics, and β blockers. Indications,
contraindications, potential complications, and conditions that require the careful use of drugs must be consid-
ered. Although significant progress has been made in the treatment of hypertension, management is still often in-
adequate. Development of more effective treatments will result in improvements in quality of life and prognosis
for patients with hypertension.
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Fig.　1　Changes in muscle sympathetic nerve activity 













































Pre MVD Post MVD Pre MVD Post MVD
Table　1　Findings suggesting etiology of secondary hypertension and examinations necessary for differential diagnosis
Underlying disease Suggestive findings Examinations necessary for differential diagnosis
Secondary hypertension in general Severe hypertension, resistant hyperten-
sion, hypertensive crisis and juvenile hyper-
tension
Renovascular hypertension Rapid deterioration of the renal function af-
ter the administration of RA system inhibi-
tors, laterality in the kedney size, hypokale-
mia and abdominal vascular bruit
Renal artery ultrasonography, abdominal 
CTA, abdominal MRA, renoscintigraphy, 
PRA and PAC
Renal parenchymal hypertension Increase in the serum Cr level, proteinuria, 
hematuria and a history of kidney disease
Seroimmunological test, abdominal CT, ul-
trasonography and kidney biopsy
Primary aldosteronism Hypokalemia, adrenal incidentaloma PRA, PAC, load test, adrenal CT and adre-
nal venous blood collection
Sleep apnea syndrome Snoring, obesity, daytime sleepiness and 
morning/nighttime hypertension
Polysomnography
Pheochromocytoma Paroxysmal/labile hypertension, palpitation, 
headache and sweating
Blood/urinary catecholamines and their 
metaboites, abdominal ultrasonography/CT 
and MIBG scintigraphy
Cushing’s syndrome Central obesity, moon face, striated skin 
and hyperglycemia
Cortisol, ACTH, abdominal CT, cephalic 
MRI and dexamethasone suppression test
Sub-clinilal Cushing’s syndrome Adrenal incidentaloma Cortisol, ACTH, abdominal CT and dexa-
methasone suppression test
Drug-induced hypertension Previous drug administration, hypokalemia Confirmation of previously administered 
drugs
Aortic coarctation Differences in blood pressure between the 
upper and lower limbs, vascular murmurs
Thoracic/abdominal CT, MRI/MRA and an-
giography
Hypothyroidism Bradycardia, edema, hypoactivity and in-
creases in the levels of lipids, CPK and LDH
Thyroid hormome, TSH, autoantibody and 
thyroid ultrasonography
Hyperthyroidism Tachycardia, sweating, weight loss and a 
decrease in the cholesterol level
Thyroid hormone, TSH, autoantibody and 
thyroid ultrasonography
Hyperparathyroidism Hypercalcemia Parathyroid hormone
Brainstem vascular compression Facial spasm, trigeminal neuralgia Brain MRI/MRA
ACTH, adrenocorticotropic hormone; CPK, creatine phosphokinase; CTA, CT angiography; LDH, lactate dehydrogenase; MIBG, me-
taiodobenzylguanidine; MRA, magnetic resonance angiography; PAC, plasma aldosterone concentration; PRA, plasma renin activity; 






























Fig.　2　Clinical course in a patient with refractory hypertension



























Table　2　Indications for antihypertensive drugs
Ca channel blockers ARBs/ACE inhibitors Thiazide diuretics β-Blockers
Left ventricular hypertrophy ● ●




Angina pectoris ● ● b
Post myocardial infarction ● ●
CKD
　Proteinuria (－) ● ● ●
　Proteinuria (＋) ●






 (ACE inhibitors) 
ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blockers; CKD, chronic kidney disease; MetS, metabolic syndrome.
aAdministration should be started at a low dose, and the dose should be gradually increased carefully.























Fig.　3　Renin, prorenin, and (pro)renin receptor

















Table　3　Contraindications to antihypertensive drugs and conditions requiring careful use
Contraindications Conditions that require careful use
Ca channel blockers Bradycardia (non-dihydropyridines) Heart failure
ARB Pregnancy Renal artery stenosisa
Hyperkalemia
ACE inhibitors Pregnancy Renal artery stenosisa
Angioneurotic edema
Hyperkalemia
Diuretics (thiazide) Hypokalemia Gout
Pregnancy
Impaired glucose tolerance
β-Blockers Asthma Impaired glucose tolerance
Marked bradycardia Obstructive pulmonary disease
Peripheral artery disease
ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blockers.




































Fig.　4　Structure of (pro)renin receptor
SP, signal peptide; ECD, extracellular region; TM, 
transmembrane region; CD, intracellular region; s(P)




Binding region of renin or prorenin
㻿㻼 㻱㻯㻰 㼀㻹 㻯㻰
s (P)RR
Fig.　5　Scattergrams showing the relationship between estimated glomerular filtration 
rate (eGFR) and serum soluble (pro)renin receptor [s(P)RR] level
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